Haleon plc Form 6-K Summary
Business context and reporting period
Haleon plc, a UK-incorporated consumer healthcare company, filed this Form 6-K for January 2023 on January 17, 2023. The filing reports director/PDMR shareholding transactions under the UK Market Abuse Regulation and does not contain quarterly or annual financial results.
Key transaction details
| PDMR | Position | Transaction | Date | Shares | Price |
|---|---|---|---|---|---|
| Bart Derde | Chief Supply Chain Officer | Acquisition under the Share Reward Plan: 40 partnership shares and 40 matching shares | January 11, 2023 | 80 ordinary shares | £3.14 per share |
| Jooyong Lee | Head of Strategy and Office of the CEO | Acquisition under the Share Reward Plan: 40 partnership shares and 40 matching shares | January 11, 2023 | 80 ordinary shares | £3.14 per share |
Both transactions were conducted on the London Stock Exchange and notified to the company on January 12, 2023. The aggregate consideration for each PDMR was £251.20, or £502.40 in total for both PDMRs.
Financial performance and liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
Material changes, outlook, risks, and unusual items
- No material business or financial changes are disclosed.
- No management outlook, guidance, contingencies, or risk updates are provided.
- The disclosed activity consists of routine Share Reward Plan awards/acquisitions by two persons discharging managerial responsibilities.
Important facts to verify
- Confirm the 80-share allocation to each PDMR, split equally between partnership and matching shares.
- Confirm the stated price of £3.14 per share and transaction date of January 11, 2023.
- Assess any applicable dilution or equity-compensation implications using Haleon’s subsequent share-count disclosures.
- Review separate financial filings for Haleon’s operating performance, leverage, liquidity, and outlook.